Lessons to be learnt from real-world studies on immune-related adverse events with checkpoint inhibitors: a clinical perspective from pharmacovigilance

Immune-Related Adverse Events Associated with Immune Checkpoint Blockade

Postow, M. A., Sidlow, R., & Hellmann, M. D. (2018) · New England Journal of Medicine · doi:10.1056/nejmra1703481 · Cited by 4,849 · see citing works

Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer

Schmid, P., Adams, S., Rugo, H. S., Schneeweiss, A., Barrios, C. H., Iwata, H., Diéras, V., Hegg, R., Im, S.-A., Shaw Wright, G., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1809615 · Cited by 4,350 · see citing works

Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline

Brahmer, J. R., Lacchetti, C., Schneider, B. J., Atkins, M. B., Brassil, K. J., Caterino, J. M., Chau, I., Ernstoff, M. S., Gardner, J. M., Ginex, P., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.77.6385 · Cited by 3,713 · see citing works

First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer

Horn, L., Mansfield, A. S., Szczęsna, A., Havel, L., Krzakowski, M., Hochmair, M. J., Huemer, F., Losonczy, G., Johnson, M. L., Nishio, M., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1809064 · Cited by 3,586 · see citing works

Fatal Toxic Effects Associated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-analysis

Wang, D. Y., Salem, J.-E., Cohen, J. V., Chandra, S., Menzer, C., Ye, F., Zhao, S., Das, S., Beckermann, K. E., Ha, L., et al. (2018) · JAMA Oncology · doi:10.1001/jamaoncol.2018.3923 · Cited by 2,674 · see citing works

Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

Haanen, J. B. A. G., Carbonnel, F., Robert, C., Kerr, K. M., Peters, S., Larkin, J., & Jordan, K. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx225 · Cited by 2,367 · see citing works

Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance

Martins, F., Sofiya, L., Sykiotis, G. P., Lamine, F., Maillard, M., Fraga, M., Shabafrouz, K., Ribi, C., Cairoli, A., Guex-Crosier, Y., et al. (2019) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-019-0218-0 · Cited by 2,314 · see citing works

Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group

on behalf of the Society for Immunotherapy of Cancer Toxicity Management Working Group, Puzanov, I., Diab, A., Abdallah, K., Bingham, C. O., Brogdon, C., Dadu, R., Hamad, L., Kim, S., Lacouture, M. E., et al. (2017) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-017-0300-z · Cited by 1,992 · see citing works

Cardiovascular toxicities associated with immune checkpoint inhibitors: an observational, retrospective, pharmacovigilance study

Salem, J.-E., Manouchehri, A., Moey, M., Lebrun-Vignes, B., Bastarache, L., Pariente, A., Gobert, A., Spano, J.-P., Balko, J. M., Bonaca, M. P., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30608-9 · Cited by 1,271 · see citing works

Immune-related adverse events and anti-tumor efficacy of immune checkpoint inhibitors

Das, S., & Johnson, D. B. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0805-8 · Cited by 1,145 · see citing works

Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination

Boutros, C., Tarhini, A. A., Routier, É., Lambotte, O., Ladurie, F. L. R., Carbonnel, F., Izzeddine, H., Marabelle, A., Champiat, S., Berdelou, A., et al. (2016) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.58 · Cited by 1,090 · see citing works

Increased reporting of fatal immune checkpoint inhibitor-associated myocarditis

Moslehi, J. J., Salem, J.-E., Sosman, J. A., Lebrun-Vignes, B., & Johnson, D. B. (2018) · The Lancet · doi:10.1016/s0140-6736(18)30533-6 · Cited by 942 · see citing works

Tumour- and class-specific patterns of immune-related adverse events of immune checkpoint inhibitors: a systematic review

Khoja, L., Day, D., Chen, T. W., Siu, L. L., & Hansen, A. R. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx286 · Cited by 937 · see citing works

Treatment-Related Adverse Events of PD-1 and PD-L1 Inhibitors in Clinical Trials

Wang, Y., Zhou, S., Yang, F., Qi, X., Wang, X., Guan, X., Shen, C., Duma, N., Aguilera, J. V., Chintakuntlawar, A. V., et al. (2019) · JAMA Oncology · doi:10.1001/jamaoncol.2019.0393 · Cited by 880 · see citing works

Development of immuno-oncology drugs — from CTLA4 to PD1 to the next generations

Hoos, A. (2016) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2015.35 · Cited by 601 · see citing works

Immune Checkpoint Inhibitor Rechallenge After Immune-Related Adverse Events in Patients With Cancer

Dolladille, C., Éderhy, S., Sassier, M., Cautela, J., Thuny, F., Cohen, A. A., Fédrizzi, S., Chrétien, B., Silva, A. D., Plane, A., et al. (2020) · JAMA Oncology · doi:10.1001/jamaoncol.2020.0726 · Cited by 592 · see citing works

Immune-related adverse events for anti-PD-1 and anti-PD-L1 drugs: systematic review and meta-analysis

Baxi, S. S., Yang, A. W., Gennarelli, R. L., Khan, N., Wang, Z., Boyce, L. M., & Korenstein, D. R. (2018) · BMJ · doi:10.1136/bmj.k793 · Cited by 581 · see citing works

Management of Immunotherapy-Related Toxicities, Version 1.2019, NCCN Clinical Practice Guidelines in Oncology

Thompson, J. A., Schneider, B. J., Brahmer, J., Andrews, S., Armand, P., Bhatia, S., Budde, L. E., Costa, L., Davies, M., Dunnington, D., et al. (2019) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2019.0013 · Cited by 570 · see citing works

Comparative safety of immune checkpoint inhibitors in cancer: systematic review and network meta-analysis

Xu, C., Chen, Y., Du, X.-J., Liu, J.-Q., Huang, C.-L., Chen, L., Zhou, G., Li, W., Mao, Y., Hsu, C., et al. (2018) · BMJ · doi:10.1136/bmj.k4226 · Cited by 560 · see citing works

Characterization of liver injury induced by cancer immunotherapy using immune checkpoint inhibitors

Martin, E. D., Michot, J., Papouin, B., Champiat, S., Mateus, C., Lambotte, O., Roche, B., Antonini, T., Coilly, A., Laghouati, S., et al. (2018) · Journal of Hepatology · doi:10.1016/j.jhep.2018.01.033 · Cited by 552 · see citing works

Benefits and strengths of the disproportionality analysis for identification of adverse drug reactions in a pharmacovigilance database

Montastruc, J., Sommet, A., Bagheri, H., & Lapeyre‐Mestre, M. (2011) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2011.04037.x · Cited by 518 · see citing works

Incidence of Pneumonitis With Use of Programmed Death 1 and Programmed Death-Ligand 1 Inhibitors in Non-Small Cell Lung Cancer

Khunger, M., Rakshit, S., Pasupuleti, V., Hernández, A. V., Mazzone, P. J., Stevenson, J. P., Pennell, N. A., & Velcheti, V. (2017) · CHEST Journal · doi:10.1016/j.chest.2017.04.177 · Cited by 501 · see citing works

Use of Immune Checkpoint Inhibitors in the Treatment of Patients With Cancer and Preexisting Autoimmune Disease: A Systematic Review

Abdel-Wahab, N., Shah, M., Lopez-Olivo, M. A., & Suarez-Almazor, M. E. (2018) · Annals of Internal Medicine · doi:10.7326/m17-2073 · Cited by 487 · see citing works

Challenges of Guarantee-Time Bias

Giobbie‐Hurder, A., Gelber, R. D., & Regan, M. M. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2013.49.5283 · Cited by 463 · see citing works

Association of Checkpoint Inhibitor-Induced Toxic Effects With Shared Cancer and Tissue Antigens in Non-Small Cell Lung Cancer

Berner, F., Bomze, D., Diem, S., Ali, O. H., Fässler, M., Ring, S., Niederer, R., Ackermann, C. J., Baumgaertner, P., Pikor, N., et al. (2019) · JAMA Oncology · doi:10.1001/jamaoncol.2019.0402 · Cited by 395 · see citing works

Immune-Related Adverse Events (irAEs): Diagnosis, Management, and Clinical Pearls

Darnell, E. P., Mooradian, M. J., Baruch, E. N., Yilmaz, M., & Reynolds, K. L. (2020) · Current Oncology Reports · doi:10.1007/s11912-020-0897-9 · Cited by 384 · see citing works

Evaluation of Readministration of Immune Checkpoint Inhibitors After Immune-Related Adverse Events in Patients With Cancer

Simonaggio, A., Michot, J., Voisin, A.-L., Pavec, J. L., Collins, M., Lallart, A., Cengizalp, G., Vozy, A., Laparra, A., Varga, A., et al. (2019) · JAMA Oncology · doi:10.1001/jamaoncol.2019.1022 · Cited by 383 · see citing works

Neurologic toxicity associated with immune checkpoint inhibitors: a pharmacovigilance study

Johnson, D. B., Manouchehri, A., Haugh, A. M., Quach, H. T., Balko, J. M., Lebrun‐Vignes, B., Mammen, A. L., Moslehi, J. J., & Salem, J. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0617-x · Cited by 368 · see citing works

Pembrolizumab Treatment for Progressive Multifocal Leukoencephalopathy

Cortese, I. C. M., Muranski, P. J., Enose‐Akahata, Y., Ha, S.-K., Smith, B., Monaco, M. C., Ryschkewitsch, C. F., Major, E. O., Ohayon, J. M., Schindler, M. K., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1815039 · Cited by 362 · see citing works

Performance of Pharmacovigilance Signal-Detection Algorithms for the FDA Adverse Event Reporting System

Harpaz, R., DuMouchel, W., LePendu, P., Bauer‐Mehren, A., Ryan, P. B., & Shah, N. H. (2013) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2013.24 · Cited by 341 · see citing works

EGFR–TKI-Associated Interstitial Pneumonitis in Nivolumab-Treated Patients With Non–Small Cell Lung Cancer

Oshima, Y., Tanimoto, T., Yuji, K., & Tojo, A. (2018) · JAMA Oncology · doi:10.1001/jamaoncol.2017.4526 · Cited by 313 · see citing works

Diagnosis and management of toxicities of immune checkpoint inhibitors in hepatocellular carcinoma

Sangro, B., Chan, S. L., Meyer, T., Reig, M., El-Khoueiry, A. B., & Galle, P. R. (2020) · Journal of Hepatology · doi:10.1016/j.jhep.2019.10.021 · Cited by 294 · see citing works

Data Mining Techniques in Pharmacovigilance: Analysis of the Publicly Accessible FDA Adverse Event Reporting System (AERS)

Poluzzi, E., Raschi, E., Piccinni, C. P., & De, F. (2012) · InTech eBooks · doi:10.5772/50095 · Cited by 227 · see citing works

Immune Checkpoint Inhibitor–Associated Myositis

Anquetil, C., Salem, J., Lebrun‐Vignes, B., Johnson, D. B., Mammen, A. L., Stenzel, W., Léonard-Louis, S., Benvéniste, O., Moslehi, J. J., & Allenbach, Y. (2018) · Circulation · doi:10.1161/circulationaha.118.035898 · Cited by 200 · see citing works

Empirical estimation of under-reporting in the U.S. Food and Drug Administration Adverse Event Reporting System (FAERS)

Alatawi, Y. M., & Hansen, R. A. (2017) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2017.1323867 · Cited by 194 · see citing works

Endocrine toxicity of immune checkpoint inhibitors: a real-world study leveraging US Food and Drug Administration adverse events reporting system

Zhai, Y., Ye, X., Hu, F., Xu, J., Guo, X., Zhuang, Y., & He, J. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0754-2 · Cited by 191 · see citing works

New therapeutic perspectives to manage refractory immune checkpoint-related toxicities

Martins, F., Sykiotis, G. P., Maillard, M. H., Fraga, M. C., Ribi, C., Küntzer, T., Michielin, O. A., Peters, S., Coukos, G., Spertini, F., et al. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30828-3 · Cited by 190 · see citing works

Imaging and clinicopathological features of nivolumab-related cholangitis in patients with non-small cell lung cancer

Kawakami, H., Tanizaki, J., Tanaka, K., Haratani, K., Hayashi, H., Takeda, M., Kamata, K., Takenaka, M., Kimura, M., Chikugo, T., et al. (2017) · Investigational New Drugs · doi:10.1007/s10637-017-0453-0 · Cited by 177 · see citing works

Hematologic Complications of Immune Checkpoint Inhibitors

Davis, E. J., Salem, J., Young, A., Green, J. R., Ferrell, P. B., Ancell, K. K., Lebrun‐Vignes, B., Moslehi, J. J., & Johnson, D. B. (2019) · The Oncologist · doi:10.1634/theoncologist.2018-0574 · Cited by 177 · see citing works

Good Signal Detection Practices: Evidence from IMI PROTECT

Wisniewski, A. F. Z., Bate, A., Cédric Bousquet, B., Brueckner, A., Candore, G., Juhlin, K., Maciá, M. A., Manlik, K., Quarcoo, N., Seabroke, S., et al. (2016) · Drug Safety · doi:10.1007/s40264-016-0405-1 · Cited by 152 · see citing works

Immune-related adverse events associated with programmed cell death protein-1 and programmed cell death ligand 1 inhibitors for non-small cell lung cancer: a PRISMA systematic review and meta-analysis

Sun, X., Roudi, R., Dai, T., Chen, S., Fan, B., Li, H., Zhou, Y., Zhou, M., Zhu, B., Yin, C., et al. (2019) · BMC Cancer · doi:10.1186/s12885-019-5701-6 · Cited by 149 · see citing works

Increased Reporting of Immune Checkpoint Inhibitor–Associated Diabetes

Wright, J. J., Salem, J., Johnson, D. B., Lebrun‐Vignes, B., Stamatouli, A. M., Thomas, J. W., Herold, K. C., Moslehi, J. J., & Powers, A. C. (2018) · Diabetes Care · doi:10.2337/dc18-1465 · Cited by 127 · see citing works

Immune Checkpoint Inhibitor Toxicity

Palmieri, D. J., & Carlino, M. S. (2018) · Current Oncology Reports · doi:10.1007/s11912-018-0718-6 · Cited by 123 · see citing works

Pharmacovigilance of sodium-glucose co-transporter-2 inhibitors: what a clinician should know on disproportionality analysis of spontaneous reporting systems

Raschi, E., Poluzzi, E., Salvo, F., Pariente, A., De Ponti, F., Marchesini, G., & Moretti, U. (2018) · Nutrition, Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2018.02.014 · Cited by 119 · see citing works

Multiple sclerosis outcomes after cancer immunotherapy

García, C. R., Jayswal, R. D., Adams, V. R., Anthony, L. B., & Villano, J. L. (2019) · Clinical & Translational Oncology · doi:10.1007/s12094-019-02060-8 · Cited by 115 · see citing works

Adverse Event Profiles of Anti-CTLA-4 and Anti-PD-1 Monoclonal Antibodies Alone or in Combination: Analysis of Spontaneous Reports Submitted to FAERS

Ji, H., Tang, X., Dong, Z. W., Song, L., & Jia, Y. (2019) · Clinical Drug Investigation · doi:10.1007/s40261-018-0735-0 · Cited by 110 · see citing works

Programmed cell death-1 inhibitor-related sclerosing cholangitis: A systematic review

Onoyama, T., Takeda, Y., Yamashita, T., Hamamoto, W., Sakamoto, Y., Koda, H., Kawata, S., Matsumoto, K., & Isomoto, H. (2020) · World Journal of Gastroenterology · doi:10.3748/wjg.v26.i3.353 · Cited by 109 · see citing works

Can Disproportionality Analysis of Post-marketing Case Reports be Used for Comparison of Drug Safety Profiles?

Michel, C., Scosyrev, E., Petrin, M., & Schmouder, R. (2017) · Clinical Drug Investigation · doi:10.1007/s40261-017-0503-6 · Cited by 105 · see citing works

Safety and Tolerability of Immune Checkpoint Inhibitors (PD-1 and PD-L1) in Cancer

Baraibar, I., Melero, I., Ponz‐Sarvisé, M., & Álvarez, E. C. (2019) · Drug Safety · doi:10.1007/s40264-018-0774-8 · Cited by 103 · see citing works

Ocular adverse events with immune checkpoint inhibitors

Fang, T., Maberley, D., & Etminan, M. (2019) · Journal of Current Ophthalmology · doi:10.1016/j.joco.2019.05.002 · Cited by 102 · see citing works

Nivolumab-induced cholangitic liver disease: a novel form of serious liver injury

Gelsomino, F., Vitale, G., D’Errico, A., Bertuzzi, C. A., Andreoné, P., & Ardizzoni, A. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw649 · Cited by 101 · see citing works

Toxicities with immune checkpoint inhibitors: emerging priorities from disproportionality analysis of the FDA adverse event reporting system

Raschi, E., Mazzarella, A., Antonazzo, I. C., Bendinelli, N., Forcesi, E., Tuccori, M., Moretti, U., Poluzzi, E., & De Ponti, F. (2019) · Targeted Oncology · doi:10.1007/s11523-019-00632-w · Cited by 101 · see citing works

Late cardiac adverse events in patients with cancer treated with immune checkpoint inhibitors

Dolladille, C., Éderhy, S., Allouche, S., Dupas, Q., Gervais, R., Madelaine, J., Sassier, M., Plane, A., Comoz, F., Cohen, A. A., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2019-000261 · Cited by 98 · see citing works

Clinical Characteristics and Adverse Impact of Hepatotoxicity due to Immune Checkpoint Inhibitors

Miller, E., Abu‐Sbeih, H., Styskel, B. A., Nogueras‐González, G. M., Blechacz, B. R. A., Naing, A., & Chalasani, N. (2019) · The American Journal of Gastroenterology · doi:10.14309/ajg.0000000000000398 · Cited by 97 · see citing works

Autoimmune hemolytic anemia associated with the use of immune checkpoint inhibitors for cancer: 68 cases from the Food and Drug Administration database and review

Tanios, G. E., Doley, P. B., & Munker, R. (2018) · European Journal Of Haematology · doi:10.1111/ejh.13187 · Cited by 95 · see citing works

Liver injury is most commonly due to hepatic metastases rather than drug hepatotoxicity during pembrolizumab immunotherapy

Tsung, I., Dolan, R. D., Lao, C. D., Fecher, L. A., Riggenbach, K., Yeboah‐Korang, A., & Fontana, R. J. (2019) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.15413 · Cited by 91 · see citing works

Haemophagocytic lymphohistiocytosis in patients treated with immune checkpoint inhibitors: analysis of WHO global database of individual case safety reports

Noseda, R., Bertoli, R., Müller, L., & Ceschi, A. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0598-9 · Cited by 88 · see citing works

Immune-Related Adverse Events by Immune Checkpoint Inhibitors Significantly Predict Durable Efficacy Even in Responders with Advanced Non-Small Cell Lung Cancer

Akamatsu, H., Murakami, E., Oyanagi, J., Shibaki, R., Kaki, T., Takase, E., Tanaka, M., Harutani, Y., Yamagata, N., Okuda, Y., et al. (2019) · The Oncologist · doi:10.1634/theoncologist.2019-0299 · Cited by 78 · see citing works

Bile duct obstruction in a patient treated with nivolumab as second-line chemotherapy for advanced non-small-cell lung cancer: a case report

Kashima, J., Okuma, Y., Shimizuguchi, R., & Chiba, K. (2017) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-017-2062-3 · Cited by 73 · see citing works

Serious Adverse Drug Events Reported to the FDA: Analysis of the FDA Adverse Event Reporting System 2006-2014 Database

Sonawane, K., Cheng, N., & Hansen, R. A. (2018) · Journal of Managed Care & Specialty Pharmacy · doi:10.18553/jmcp.2018.24.7.682 · Cited by 72 · see citing works

An Empirical Approach to Explore the Relationship Between Measures of Disproportionate Reporting and Relative Risks from Analytical Studies

Maciá, M. A., de Abajo, F. J., Roberts, G., Slattery, J., Thakrar, B. T., & Wisniewski, A. F. Z. (2015) · Drug Safety · doi:10.1007/s40264-015-0351-3 · Cited by 65 · see citing works

Adverse events associated with immune checkpoint inhibitor treatment for cancer

Esfahani, K., Meti, N., Miller, W. H., & Hudson, M. (2019) · Canadian Medical Association Journal · doi:10.1503/cmaj.180870 · Cited by 65 · see citing works

Mapping the Safety Profile of Biologicals

Giezen, T. J., Mantel-Teeuwisse, A. K., Meyboom, R. H. B., Straus, S. M. J. M., Leufkens, H. G. M., & Egberts, T. C. G. (2010) · Drug Safety · doi:10.2165/11538330-000000000-00000 · Cited by 54 · see citing works

A case of nivolumab-related cholangitis and literature review: how to look for the right tools for a correct diagnosis of this rare immune-related adverse event

Gelsomino, F., Vitale, G., & Ardizzoni, A. (2017) · Investigational New Drugs · doi:10.1007/s10637-017-0484-6 · Cited by 52 · see citing works

Takotsubo Syndrome in Patients with Cancer Treated with Immune Checkpoint Inhibitors: A New Adverse Cardiac Complication

Éderhy, S., Dolladille, C., Thuny, F., Alexandre, J., & Cohen, A. A. (2019) · European Journal of Heart Failure · doi:10.1002/ejhf.1497 · Cited by 51 · see citing works

Myocarditis following the use of different immune checkpoint inhibitor regimens: A real-world analysis of post-marketing surveillance data

Fan, Q., Hu, Y., Yang, C., & Zhao, B. (2019) · International Immunopharmacology · doi:10.1016/j.intimp.2019.105866 · Cited by 48 · see citing works

Evolving Roles of Spontaneous Reporting Systems to Assess and Monitor Drug Safety

Raschi, E., Moretti, U., Salvo, F., Pariente, A., Antonazzo, I. C., Ponti, F. D., & Poluzzi, E. (2019) · IntechOpen eBooks · doi:10.5772/intechopen.79986 · Cited by 48 · see citing works

Incidence and Management of Immune-Related Adverse Events in Patients Undergoing Treatment with Immune Checkpoint Inhibitors

Kottschade, L. A. (2018) · Current Oncology Reports · doi:10.1007/s11912-018-0671-4 · Cited by 47 · see citing works

Serious Cutaneous Toxicities with Immune Checkpoint Inhibitors in the U.S. Food and Drug Administration Adverse Event Reporting System

Raschi, E., Antonazzo, I. C., Plaça, M. L., Ardizzoni, A., Poluzzi, E., & Ponti, F. D. (2019) · The Oncologist · doi:10.1634/theoncologist.2019-0250 · Cited by 46 · see citing works

Rheumatic disorders associated with immune checkpoint inhibitors: what about myositis? An analysis of the WHO’s adverse drug reactions database

Nguyěn, T., Maria, A. T. J., Ladhari, C., Palassin, P., Quantin, X., Lesage, C., Taïeb, G., Ayrignac, X., Rullier, P., Hillaire‐Buys, D., et al. (2020) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2020-217018 · Cited by 45 · see citing works

Safety Profile of Biological Medicines as Compared with Non-Biologicals: An Analysis of the Italian Spontaneous Reporting System Database

Cutroneo, P. M., Isgrò, V., Russo, A., Ientile, V., Sottosanti, L., Pimpinella, G., Conforti, A., Moretti, U., Caputi, A. P., & Trifirò, G. (2014) · Drug Safety · doi:10.1007/s40264-014-0224-1 · Cited by 44 · see citing works

When to publish measures of disproportionality derived from spontaneous reporting databases?

de Boer, A. (2011) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2011.04087.x · Cited by 41 · see citing works

Workup and Management of Immune-Mediated Hepatobiliary Pancreatic Toxicities That Develop During Immune Checkpoint Inhibitor Treatment

Hsu, C. C.-S., Marshall, J. L., & He, A. R. (2019) · The Oncologist · doi:10.1634/theoncologist.2018-0162 · Cited by 41 · see citing works

Pharmacovigilance Assessment of Immune‐Mediated Reactions Reported for Checkpoint Inhibitor Cancer Immunotherapies

Ali, A. K., & Watson, D. E. (2017) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.2035 · Cited by 39 · see citing works

Antiprogrammed Cell Death‐1 Immunotherapy‐Related Secondary Sclerosing Cholangitis

Ogawa, K., Kamimura, K., & Terai, S. (2018) · Hepatology · doi:10.1002/hep.30189 · Cited by 39 · see citing works

Immune checkpoint inhibitor-associated thyroid dysfunction: a disproportionality analysis using the WHO Adverse Drug Reaction Database, VigiBase

Bai, X., Chen, X., Wu, X., Huang, Y., Zhuang, Y., & Lin, X. (2019) · European Journal of Endocrinology · doi:10.1530/eje-19-0535 · Cited by 37 · see citing works

Checkpoint inhibitor-associated immune arthritis

Arnaud, L., Lebrun‐Vignes, B., & Salem, J. (2018) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2018-213470 · Cited by 35 · see citing works

Drug-induced systemic lupus erythematosus: should immune checkpoint inhibitors be added to the evolving list?

Raschi, E., Antonazzo, I. C., Poluzzi, E., & Ponti, F. D. (2019) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2019-215819 · Cited by 34 · see citing works

Increased reporting of fatal pneumonitis associated with immune checkpoint inhibitors: a WHO pharmacovigilance database analysis

Moey, M., Gougis, P., Goldschmidt, V., Johnson, D. B., Lebrun‐Vignes, B., Moslehi, J. J., Cadranel, J. L., & Salem, J. (2020) · European Respiratory Journal · doi:10.1183/13993003.00038-2020 · Cited by 34 · see citing works

Impact of Concomitant Medication Use and Immune-Related Adverse Events on Response to Immune Checkpoint Inhibitors

Gandhi, S., Pandey, M. R., Ammannagari, N., Wang, C., Bucsek, M. J., Hamad, L., Repasky, E. A., & Ernstoff, M. S. (2020) · Immunotherapy · doi:10.2217/imt-2019-0064 · Cited by 33 · see citing works

Adverse reactions to oncologic drugs: spontaneous reporting and signal detection

Tuccori, M., Montagnani, S., Capogrosso-Sansone, A., Mantarro, S., Antonioli, L., Fornai, M., & Blandizzi, C. (2014) · Expert Review of Clinical Pharmacology · doi:10.1586/17512433.2015.974555 · Cited by 33 · see citing works

Diagnosis and Management of Rare Immune-Related Adverse Events

Schoenfeld, S. R., Aronow, M. E., Leaf, R. K., Dougan, M. L., & Reynolds, K. L. (2019) · The Oncologist · doi:10.1634/theoncologist.2019-0083 · Cited by 32 · see citing works

Immune checkpoint inhibitor–associated hypophysitis—World Health Organisation VigiBase report analysis

Guerrero, E. P., Johnson, D. B., Bachelot, A., Lebrun‐Vignes, B., Moslehi, J. J., & Salem, J. (2019) · European Journal of Cancer · doi:10.1016/j.ejca.2019.03.002 · Cited by 30 · see citing works

The Contribution of National Spontaneous Reporting Systems to Detect Signals of Torsadogenicity: Issues Emerging from the ARITMO Project

Raschi, E., Poluzzi, E., Salvo, F., Koci, A., Suling, M., Antoniazzi, S., Perina, L., Hazell, L., Moretti, U., Sturkenboom, M., et al. (2015) · Drug Safety · doi:10.1007/s40264-015-0353-1 · Cited by 29 · see citing works

Review article: immune checkpoint inhibitors and the liver, from therapeutic efficacy to side effects

Lombardi, A., & Mondelli, M. U. (2019) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.15449 · Cited by 29 · see citing works

New oncologic emergencies: What is there to know about inmunotherapy and its potential side effects?

Barquín, A., Molina‐Cerrillo, J., Garrido, P., Garcia-Palos, D., Carrato, A., & Alonso‐Gordoa, T. (2019) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2019.05.020 · Cited by 27 · see citing works

Disproportionality analysis of bullous pemphigoid adverse events with PD-1 inhibitors in the FDA adverse event reporting system

Aggarwal, P. (2019) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2019.1619693 · Cited by 27 · see citing works

Increased reporting of fatal hepatitis associated with immune checkpoint inhibitors

Vozy, A., Martin, E. D., Johnson, D. B., Lebrun‐Vignes, B., Moslehi, J. J., & Salem, J. (2019) · European Journal of Cancer · doi:10.1016/j.ejca.2019.09.022 · Cited by 27 · see citing works

Adverse events 2.0—Let us get SERIOs

Heinzerling, L., Ascierto, P. A., Dummer, R., Gogas, H. J., Grob, J., Lebbé, C., Long, G. V., McArthur, G. A., Moslehi, J. J., Neilan, T. G., et al. (2019) · European Journal of Cancer · doi:10.1016/j.ejca.2019.01.015 · Cited by 24 · see citing works

An Evaluation of Postmarketing Reports with an Outcome of Death in the US FDA Adverse Event Reporting System

Marwitz, K. K., Jones, S. C., Kortepeter, C. M., Pan, G. J. D., & Muñoz, M. A. (2020) · Drug Safety · doi:10.1007/s40264-020-00908-5 · Cited by 24 · see citing works

An Evaluation of “Drug Ineffective” Postmarketing Reports in Drug Safety Surveillance

Misu, T., Kortepeter, C. M., Muñoz, M. A., Wu, E., & Pan, G. J. D. (2018) · Drugs - Real World Outcomes · doi:10.1007/s40801-018-0131-3 · Cited by 23 · see citing works

ESC position paper on cardiovascular toxicity of cancer treatments: challenges and expectations

Raschi, E., Diemberger, I., Cosmi, B., & Ponti, F. D. (2017) · Internal and Emergency Medicine · doi:10.1007/s11739-017-1755-0 · Cited by 22 · see citing works

Development of mild drug-induced sclerosing cholangitis after discontinuation of nivolumab

Noda‐Narita, S., Mizuno, S., Noguchi, S. F., Watanabe, K., Nakai, Y., Koike, K., Kage, H., & Nagase, T. (2018) · European Journal of Cancer · doi:10.1016/j.ejca.2018.11.021 · Cited by 22 · see citing works

The impact of database restriction on pharmacovigilance signal detection of selected cancer therapies

Hauben, M., Hung, E. Y., Wood, J., Soitkar, A. M., & Reshef, D. S. (2017) · Therapeutic Advances in Drug Safety · doi:10.1177/2042098616685010 · Cited by 20 · see citing works

Comparative Safety of Targeted Therapies for Metastatic Colorectal Cancer between Elderly and Younger Patients: a Study Using the International Pharmacovigilance Database

Gouverneur, A., Claraz, P., Rousset, M., Arnaud, M., Fourrier‐Réglat, A., Pariente, A., Aparicio, T., Miremont‐Salamé, G., & Noïze, P. (2017) · Targeted Oncology · doi:10.1007/s11523-017-0529-y · Cited by 18 · see citing works

Inflammatory bowel disease associated with the combination treatment of nivolumab and metformin: data from the FDA adverse event reporting system

Zhou, H., Liu, J., Zhang, Y., & Zhang, L. (2019) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-018-03763-5 · Cited by 17 · see citing works

Solid organ transplant rejection associated with immune-checkpoint inhibitors

Saberianfar, S., Nguyen, L. S., Manouchehri, A., Lebrun‐Vignes, B., Moslehi, J. J., Johnson, D. B., Hertig, A., & Salem, J. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.01.012 · Cited by 17 · see citing works

Novel Immunotherapy Combinations

Bashir, B., & Wilson, M. A. (2019) · Current Oncology Reports · doi:10.1007/s11912-019-0851-x · Cited by 14 · see citing works

Signal of potentially protective drug–drug interactions from spontaneous reporting systems: proceed with caution

Antonazzo, I. C., Poluzzi, E., Forcesi, E., Salvo, F., Pariente, A., Marchesini, G., Ponti, F. D., & Raschi, E. (2019) · Acta Diabetologica · doi:10.1007/s00592-019-01441-3 · Cited by 7 · see citing works

Bullous disorders associated with PD-1 and PD-L1 inhibitors: Pharmacovigilance analysis of the United States Food and Drug Administration Adverse Event Reporting System from the Research on Adverse Drug Events And Reports Program

Jiménez, J., Gwillim, E. C., Kosche, C., Figueiredo, A., Rauck, C., Rangel, S. M., Choi, J. N., West, D. P., Nardone, B., & Lacouture, M. E. (2020) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2020.01.059 · Cited by 6 · see citing works

Immune-mediated cholangitis: is it always nivolumab’s fault?

Gelsomino, F., Vitale, G., & Ardizzoni, A. (2018) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-018-2159-3 · Cited by 6 · see citing works

Reduced neuropsychiatric events as “beneficial reactions” to drugs: Seek associations with caution

Raschi, E., Poluzzi, E., & Ponti, F. D. (2019) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2019.11.011 · Cited by 5 · see citing works

Authors’ Reply to Alain Braillon’s Comment on “The Contribution of National Spontaneous Reporting Systems to Detect Signals of Torsadogenicity: Issues Emerging from the ARITMO Project”

Raschi, E., Poluzzi, E., Salvo, F., Moretti, U., & Ponti, F. D. (2016) · Drug Safety · doi:10.1007/s40264-016-0404-2 · Cited by 4 · see citing works

Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: ASCO Guideline Update

Schneider, B. J., Naidoo, J., Santomasso, B., Lacchetti, C., Adkins, S., Anadkat, M., Atkins, M. B., Brassil, K. J., Caterino, J. M., Chau, I., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.21.01440 · Cited by 2,434 · see citing works

Clinical cancer immunotherapy: Current progress and prospects

Liu, C., Yang, M., Zhang, D., Chen, M., & Zhu, D. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.961805 · Cited by 249 · see citing works

Conducting and interpreting disproportionality analyses derived from spontaneous reporting systems

Cutroneo, P. M., Sartori, D., Tuccori, M., Crisafulli, S., Battini, V., Carnovale, C., Rafaniello, C., Capuano, A., Poluzzi, E., Moretti, U., et al. (2024) · Frontiers in Drug Safety and Regulation · doi:10.3389/fdsfr.2023.1323057 · Cited by 224 · see citing works

Adverse Cardiovascular and Pulmonary Events Associated With Chimeric Antigen Receptor T-Cell Therapy

Goldman, A., Maor, E., Bomze, D., Liu, J. E., Herrmann, J., Fein, J. A., Steingart, R. M., Mahmood, S., Schaffer, W. L., Perales, M., et al. (2021) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2021.08.044 · Cited by 157 · see citing works

Immune-related adverse events associated with immune checkpoint inhibitors: An updated comprehensive disproportionality analysis of the FDA adverse event reporting system

Chen, C., Wu, B., Zhang, C., & Xu, T. (2021) · International Immunopharmacology · doi:10.1016/j.intimp.2021.107498 · Cited by 135 · see citing works

Cyclin-dependent kinase 4/6 inhibitors and interstitial lung disease in the FDA adverse event reporting system: a pharmacovigilance assessment

Raschi, E., Fusaroli, M., Ardizzoni, A., Poluzzi, E., & Ponti, F. D. (2020) · Breast Cancer Research and Treatment · doi:10.1007/s10549-020-06001-w · Cited by 106 · see citing works

Therapeutic and Prognostic Implications of Immune-Related Adverse Events in Advanced Non-Small-Cell Lung Cancer

Daniello, L., Elshiaty, M., Bozorgmehr, F., Kuon, J., Kazdal, D. N., Schindler, H., Shah, R., Volckmar, A., Lusky, F., Diekmann, L., et al. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.703893 · Cited by 68 · see citing works

Skin Toxicities with Cyclin-Dependent Kinase 4/6 Inhibitors in Breast Cancer: Signals from Disproportionality Analysis of the FDA Adverse Event Reporting System

Raschi, E., Fusaroli, M., Plaça, M. L., Ardizzoni, A., Zamagni, C., Poluzzi, E., & Ponti, F. D. (2021) · American Journal of Clinical Dermatology · doi:10.1007/s40257-021-00645-0 · Cited by 61 · see citing works

Post-Marketing Surveillance of CAR-T-Cell Therapies: Analysis of the FDA Adverse Event Reporting System (FAERS) Database

Fusaroli, M., Isgrò, V., Cutroneo, P. M., Ferrajolo, C., Cirillo, V., Bufalo, F. D., Raschi, E., Poluzzi, E., & Trifirò, G. (2022) · Drug Safety · doi:10.1007/s40264-022-01194-z · Cited by 59 · see citing works

Emerging Toxicities of Antibody-Drug Conjugates for Breast Cancer: Clinical Prioritization of Adverse Events from the FDA Adverse Event Reporting System

Cecco, S., Puligheddu, S., Fusaroli, M., Gerratana, L., Yan, M., Zamagni, C., Ponti, F. D., & Raschi, E. (2024) · Targeted Oncology · doi:10.1007/s11523-024-01058-9 · Cited by 52 · see citing works

A meta-epidemiological study found lack of transparency and poor reporting of disproportionality analyses for signal detection in pharmacovigilance databases

Khouri, C., Revol, B., Lepelley, M., Mouffak, A., Bernardeau, C., Salvo, F., Pariente, A., Roustit, M., & Cracowski, J. (2021) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2021.07.014 · Cited by 48 · see citing works

Immune-related adverse events associated with immune checkpoint inhibitors: a call to action for collecting and sharing clinical trial and real-world data

Reynolds, K. L., Arora, S., Elayavilli, R. K., Louv, W. C., Schaller, T. H., Khandelwal, A., Rothenberg, M. L., Khozin, S., Guidon, A. C., Dougan, M. L., et al. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-002896 · Cited by 48 · see citing works

The evolving role of disproportionality analysis in pharmacovigilance

Fusaroli, M., Raschi, E., Poluzzi, E., & Hauben, M. (2024) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2024.2368817 · Cited by 47 · see citing works

Cardiovascular Toxicity of Immune Checkpoint Inhibitors: A Guide for Clinicians

Raschi, E., Rossi, S., Giglio, A. D., Fusaroli, M., Burgazzi, F., Rinaldi, R., & Potena, L. (2023) · Drug Safety · doi:10.1007/s40264-023-01320-5 · Cited by 47 · see citing works

Bone fracture as a novel immune‐related adverse event with immune checkpoint inhibitors: Case series and large‐scale pharmacovigilance analysis

Filippini, D. M., Gatti, M., Martino, V. D., Cavalieri, S., Fusaroli, M., Ardizzoni, A., Raschi, E., & Licitra, L. F. (2021) · International Journal of Cancer · doi:10.1002/ijc.33592 · Cited by 45 · see citing works

Thromboembolic Events with Cyclin-Dependent Kinase 4/6 Inhibitors in the FDA Adverse Event Reporting System

Raschi, E., Fusaroli, M., Ardizzoni, A., Poluzzi, E., & Ponti, F. D. (2021) · Cancers · doi:10.3390/cancers13081758 · Cited by 45 · see citing works

Managing potential adverse events during treatment with enfortumab vedotin + pembrolizumab in patients with advanced urothelial cancer

Brower, B., McCoy, A. S., Ahmad, H., Eitman, C., Bowman, I. A., Rembisz, J., & Milowsky, M. I. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1326715 · Cited by 44 · see citing works

Janus Kinase Inhibitors and Coronavirus Disease (COVID)-19: Rationale, Clinical Evidence and Safety Issues

Gatti, M., Turrini, E., Raschi, E., Sestili, P., & Fimognari, C. (2021) · Pharmaceuticals · doi:10.3390/ph14080738 · Cited by 42 · see citing works

Sex differences in immune-related adverse events with immune checkpoint inhibitors: data mining of the FDA adverse event reporting system

Chen, C., Zhang, C., Jin, Z., Wu, B., & Xu, T. (2022) · International Journal of Clinical Pharmacy · doi:10.1007/s11096-022-01395-7 · Cited by 38 · see citing works

Immune Checkpoint Inhibitors and Pregnancy: Analysis of the VigiBase® Spontaneous Reporting System

Noseda, R., Müller, L., Bedussi, F., Fusaroli, M., Raschi, E., & Ceschi, A. (2022) · Cancers · doi:10.3390/cancers15010173 · Cited by 37 · see citing works

Immune checkpoint inhibitors-related myocarditis in patients with cancer: an analysis of international spontaneous reporting systems

Ma, R., Wang, Q., Meng, D., Li, K., & Zhang, Y. (2021) · BMC Cancer · doi:10.1186/s12885-020-07741-0 · Cited by 37 · see citing works

Hyperglycaemic disorders associated with PCSK9 inhibitors: a real-world, pharmacovigilance study

Goldman, A., Raschi, E., Cukierman‐Yaffe, T., Dankner, R. S., Shouval, R., Shechter, M., Ben‐Zvi, I., Gerstein, H. C., & Maor, E. (2021) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwab209 · Cited by 37 · see citing works

Distinct immune-effector and metabolic profile of CD8+ T cells in patients with autoimmune polyarthritis induced by therapy with immune checkpoint inhibitors

Benesova, K., Kraus, F. V., Carvalho, R. A., Lorenz, H., Hoerth, C. H., Günther, J., Klika, K. D., Graf, J., Diekmann, L., Schank, T. E., et al. (2022) · Annals of the Rheumatic Diseases · doi:10.1136/ard-2022-222451 · Cited by 35 · see citing works

A real-world pharmacovigilance study investigating the toxicities of histone deacetylase inhibitors

Li, W., Fu, Y., & Wang, W. (2024) · Annals of Hematology · doi:10.1007/s00277-024-05691-2 · Cited by 35 · see citing works

Adverse cardiovascular events in rheumatoid arthritis patients treated with JAK inhibitors: An analysis of postmarketing spontaneous safety reports

Goldman, A., Galper, B.-E. L., Druyan, A., Grossman, C., Sharif, Κ., Shechtman, L., Moshkovits, Y., Lahat, A., & Ben‐Zvi, I. (2024) · Seminars in Arthritis and Rheumatism · doi:10.1016/j.semarthrit.2024.152461 · Cited by 33 · see citing works

Cardiovascular Toxicities of Antiangiogenic Tyrosine Kinase Inhibitors: A Retrospective, Pharmacovigilance Study

Goldman, A., Bomze, D., Dankner, R. S., Fourey, D., Boursi, B., Arad, M., & Maor, E. (2021) · Targeted Oncology · doi:10.1007/s11523-021-00817-2 · Cited by 32 · see citing works

Cutaneous Toxicities Associated with Immune Checkpoint Inhibitors: An Observational, Pharmacovigilance Study

Le, T. K., Brown, I. D., Goldberg, R., Taylor, M. T., Deng, J., Parthasarathy, V., Bordeaux, Z. A., Alphonse, M. P., Kwatra, M. M., Naranbhai, V., et al. (2022) · Journal of Investigative Dermatology · doi:10.1016/j.jid.2022.04.020 · Cited by 32 · see citing works

Safety profile of monoclonal antibodies targeting the calcitonin gene-related peptide system in pregnancy: Updated analysis in VigiBase®

Noseda, R., Bedussi, F., Gobbi, C., Ceschi, A., & Zecca, C. (2023) · Cephalalgia · doi:10.1177/03331024231158083 · Cited by 31 · see citing works

Pre-Existing Cardiovascular Conditions as Clinical Predictors of Myocarditis Reporting with Immune Checkpoint Inhibitors: A VigiBase Study

Noseda, R., Ruinelli, L., van der Gaag, L. C., & Ceschi, A. (2020) · Cancers · doi:10.3390/cancers12113480 · Cited by 31 · see citing works

Drug-induced interstitial lung disease: a real-world pharmacovigilance study of the FDA Adverse Event Reporting System from 2004 to 2021

Jiang, T., Su, H., Xu, J., Li, C., Zhang, N., Li, Y., Wu, Y., Ni, R., Ming, Y., Li, Z., et al. (2024) · Therapeutic Advances in Drug Safety · doi:10.1177/20420986231224227 · Cited by 30 · see citing works

Pneumocystis jirovecii pneumonia associated with immune checkpoint inhibitors: A systematic literature review of published case reports and disproportionality analysis based on the FAERS database

Xia, S., Gong, H., Wang, Y., Liu, L., Zhao, Y., Guo, L., Zhang, B., Sarangdhar, M., Noguchi, Y., & Yan, M. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1129730 · Cited by 28 · see citing works

Incidence and risk factors of immune‐related adverse events induced by immune checkpoint inhibitors among older adults with non‐small cell lung cancer

Rong, Y., Bentley, J. P., Bhattacharya, K., Yang, Y., Chang, Y., Earl, S. R., & Ramachandran, S. (2024) · Cancer Medicine · doi:10.1002/cam4.6879 · Cited by 28 · see citing works

Checkpoint Inhibitor-Induced Colitis: An Update

Losurdo, G., Angelillo, D., Favia, N., Sergi, M. C., Leo, A. D., Triggiano, G., & Tucci, M. (2023) · Biomedicines · doi:10.3390/biomedicines11051496 · Cited by 28 · see citing works

Cardiotoxicity in cancer immune-checkpoint therapy: Mechanisms, clinical evidence, and management strategies

Sun, J.-Y., Qu, Q., Lou, Y.-X., Yang, H., Sun, G.-Z., Sun, W., & Kong, X. (2021) · International Journal of Cardiology · doi:10.1016/j.ijcard.2021.09.041 · Cited by 27 · see citing works

Emerging Ocular Side Effects of Immune Checkpoint Inhibitors: A Comprehensive Review

Wu, K. Y., Yakobi, Y., Gueorguieva, D. D., & Mazerolle, É. (2024) · Biomedicines · doi:10.3390/biomedicines12112547 · Cited by 26 · see citing works

Real-world studies: bridging the gap between trial-assessed efficacy and routine care

Chen, D. (2022) · Journal of Biomedical Research · doi:10.7555/jbr.36.20220040 · Cited by 26 · see citing works

Psychiatric Adverse Reactions to Anaplastic Lymphoma Kinase Inhibitors in Non-Small-Cell Lung Cancer: Analysis of Spontaneous Reports Submitted to the FDA Adverse Event Reporting System

Sisi, M., Fusaroli, M., Giglio, A. D., Facchinetti, F., Ardizzoni, A., Raschi, E., & Gelsomino, F. (2022) · Targeted Oncology · doi:10.1007/s11523-021-00865-8 · Cited by 27 · see citing works

Reporting of late-onset immune-related adverse events with immune checkpoint inhibitors in VigiBase

Noseda, R., Bedussi, F., Giunchi, V., Fusaroli, M., Raschi, E., & Ceschi, A. (2024) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2024-009902 · Cited by 24 · see citing works

An updated review of gastrointestinal toxicity induced by PD-1 inhibitors: from mechanisms to management

Cheng, Y., Ling, F., Li, J., Chen, Y., Xu, M., Li, S., & Zhu, L. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1190850 · Cited by 23 · see citing works

Pancreatic Adverse Events Associated With Immune Checkpoint Inhibitors: A Large-Scale Pharmacovigilance Analysis

Zhang, Y., Fang, Y. V., Wu, J., Huang, G., Bin, J., Liao, Y., Shi, M., Liao, W., & Huang, N. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.817662 · Cited by 23 · see citing works

Conceiving, conducting, reporting, interpreting, and publishing disproportionality analyses: A call to action

Raschi, E., Salvo, F., & Khouri, C. (2022) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.15269 · Cited by 21 · see citing works

Mapping Strategies to Assess and Increase the Validity of Published Disproportionality Signals: A Meta-Research Study

Fusaroli, M., Salvo, F., Bernardeau, C., Idris, M., Dolladille, C., Pariente, A., Poluzzi, E., Raschi, E., & Khouri, C. (2023) · Drug Safety · doi:10.1007/s40264-023-01329-w · Cited by 21 · see citing works

Adrenal Insufficiency with Anticancer Tyrosine Kinase Inhibitors Targeting Vascular Endothelial Growth Factor Receptor: Analysis of the FDA Adverse Event Reporting System

Raschi, E., Fusaroli, M., Giunchi, V., Repaci, A., Pelusi, C., Mollica, V., Massari, F., Ardizzoni, A., Poluzzi, E., Pagotto, U., et al. (2022) · Cancers · doi:10.3390/cancers14194610 · Cited by 21 · see citing works

Post-marketing safety of immunomodulatory drugs in multiple myeloma: A pharmacovigilance investigation based on the FDA adverse event reporting system

Jiang, T., Su, H., Li, Y., Wu, Y., Ming, Y., Li, C., Fu, R., Feng, L., Li, Z., Li, L., et al. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.989032 · Cited by 19 · see citing works

The reporting of disproportionality analysis in pharmacovigilance: spotlight on the READUS-PV guideline

Fusaroli, M., Salvo, F., Khouri, C., & Raschi, E. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1488725 · Cited by 18 · see citing works

The Changing Face of Drug-induced Adrenal Insufficiency in the Food and Drug Administration Adverse Event Reporting System

Raschi, E., Fusaroli, M., Massari, F., Mollica, V., Repaci, A., Ardizzoni, A., Poluzzi, E., Pagotto, U., & Di Dalmazi, G. (2022) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgac359 · Cited by 17 · see citing works

Adverse Events Associated with Immune Checkpoint Inhibitors: Overview of Systematic Reviews

Kanji, S., Morin, S., Agtarap, K., Purkayastha, D., Thabet, P., Bossé, D., Wang, X., Lunny, C., & Hutton, B. (2022) · Drugs · doi:10.1007/s40265-022-01707-1 · Cited by 17 · see citing works

Systematic surveillance of immune-related adverse events in clinical practice and impact of subsequent steroid medication on survival outcomes

Matsukane, R., Suetsugu, K., Hata, K., Matsuda, K., Nakao, S., Minami, H., Watanabe, H. A., Hirota, T., Egashira, N., & Ieiri, I. (2023) · International Journal of Clinical Oncology · doi:10.1007/s10147-023-02349-3 · Cited by 17 · see citing works

Managing Select Immune-Related Adverse Events in Patients Treated with Immune Checkpoint Inhibitors

Cheema, P. K., Iafolla, M. A. J., Abdel-Qadir, H. M., Bellini, A. B., Chatur, N., Chandok, N., Comondore, V. R., Cunningham, M. E., Halperin, I. J., Hu, A. C., et al. (2024) · Current Oncology · doi:10.3390/curroncol31100473 · Cited by 17 · see citing works

Efficacy and safety of PD-1/PD-L1 inhibitors in patients with Merkel Cell Carcinoma: a systematic review and Meta-analysis

de Moraes, F. C. A., Kreuz, M., de Lara, I. C. A., Lôbo, A. D. O. M., & Burbano, R. M. R. (2024) · BMC Cancer · doi:10.1186/s12885-024-13129-1 · Cited by 17 · see citing works

Immune checkpoint inhibitors in melanoma: mechanisms, immune cell interactions, and the tumour microenvironment

Liang, Y., Zheng, Y., Zeng, Y., Hu, C., Si, Y., Fan, X., & Chen, Q. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1691608 · Cited by 16 · see citing works

Development of a Network-Based Signal Detection Tool: The COVID-19 Adversome in the FDA Adverse Event Reporting System

Fusaroli, M., Raschi, E., Gatti, M., Ponti, F. D., & Poluzzi, E. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.740707 · Cited by 15 · see citing works

Clinical guideline highlights for the hospitalist: Management of immune‐related adverse events in patients treated with immune checkpoint inhibitor therapy

Chitnis, S. D., & Mortazavi, A. (2023) · Journal of Hospital Medicine · doi:10.1002/jhm.13097 · Cited by 14 · see citing works

Gastrointestinal Perforations Associated With JAK Inhibitors: A Disproportionality Analysis of the FDA Adverse Event Reporting System

Goldman, A., Raschi, E., Druyan, A., Sharif, Κ., Lahat, A., Ben‐Zvi, I., & Ben‐Horin, S. (2024) · United European Gastroenterology Journal · doi:10.1002/ueg2.12736 · Cited by 14 · see citing works

Anaplastic lymphoma kinase tyrosine kinase inhibitors associated gastrointestinal obstruction, perforation, and ulceration: an analysis of the FDA adverse event reporting system database (FAERS)

Huang, J., Zhao, Y., Cao, Y., Zhang, Q., Ran, D., Li, J., Luo, L., Qiu, F., & Meng, L. (2022) · International Journal of Clinical Pharmacy · doi:10.1007/s11096-022-01425-4 · Cited by 14 · see citing works

Adverse Event Reporting with Immune Checkpoint Inhibitors in Older Patients: Age Subgroup Disproportionality Analysis in VigiBase

Noseda, R., Bonaldo, G., Motola, D., Stathis, A., & Ceschi, A. (2021) · Cancers · doi:10.3390/cancers13051131 · Cited by 14 · see citing works

Immune-related adverse events in older adults: Data mining of the FDA Adverse Event Reporting System

Chen, C., Zhang, C., Wu, B., & Xu, T. (2022) · Journal of Geriatric Oncology · doi:10.1016/j.jgo.2022.05.009 · Cited by 13 · see citing works

Impact of immune-related adverse event severity on overall survival in patients with advanced NSCLC receiving immune checkpoint inhibitors therapy, with a focus on combination regimens

Sugai, M., Amino, Y., Fujishima, S., Nibuya, K., Iso, H., Ito, M., Tsugitomi, R., Ariyasu, R., Uchibori, K., Yanagitani, N., et al. (2025) · Lung Cancer · doi:10.1016/j.lungcan.2025.108555 · Cited by 13 · see citing works

Respiratory system toxicity induced by immune checkpoint inhibitors: A real-world study based on the FDA adverse event reporting system database

Cui, C., Deng, L., Wang, W., Ren, X., Wang, Y., & Cui, W. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.941079 · Cited by 12 · see citing works

Combining Radiotherapy with Immunotherapy in Cervical Cancer: Where Do We Stand and Where Are We Going?

Peng, Y., Yan, H., Mei, W., Zhang, P., & Zeng, C. (2023) · Current Treatment Options in Oncology · doi:10.1007/s11864-023-01128-6 · Cited by 11 · see citing works

Influenza Vaccination and Myo-Pericarditis in Patients Receiving Immune Checkpoint Inhibitors: Investigating the Likelihood of Interaction through the Vaccine Adverse Event Reporting System and VigiBase

Gatti, M., Raschi, E., Moretti, U., Ardizzoni, A., Poluzzi, E., & Diemberger, I. (2021) · Vaccines · doi:10.3390/vaccines9010019 · Cited by 11 · see citing works

Relatlimab and nivolumab in untreated advanced melanoma: insight into RELATIVITY

Raschi, E., Comito, F., Massari, F., & Gelsomino, F. (2023) · Immunotherapy · doi:10.2217/imt-2022-0172 · Cited by 11 · see citing works

Safety of current immune checkpoint inhibitors in non-small cell lung cancer

Abdayem, P., & Planchard, D. (2021) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2021.1867100 · Cited by 11 · see citing works

18F-FDG PET/CT for Detection of Immunotherapy-Induced Hypophysitis—A Case-Control Study

Fischer, A., Gómez, J. M. M., Mangana, J., Dummer, R., Erlic, Z., Nölting, S., Beuschlein, F., Maurer, A. B., Messerli, M., Huellner, M. W., et al. (2024) · Clinical Nuclear Medicine · doi:10.1097/rlu.0000000000005440 · Cited by 10 · see citing works

Germline prediction of immune checkpoint inhibitor discontinuation for immune-related adverse events

Middha, P., Thummalapalli, R., Quandt, Z., Balaratnam, K., Cardenas, E. R., Falcon, C. J., Princess Margaret Lung Group, Gubens, M. A., Huntsman, S., Khan, K., et al. (2025) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2024-011273 · Cited by 12 · see citing works

Immune Checkpoint Inhibitors Related to Cardiotoxicity

Chen, R., Zhou, M., & Zhu, F. (2022) · Journal of Cardiovascular Development and Disease · doi:10.3390/jcdd9110378 · Cited by 10 · see citing works

Integrative analysis of immune molecular subtypes and microenvironment characteristics of bladder cancer

Cao, J., Li, J., Yang, X. L., Li, P., Yao, Z., Han, D., Ying, L., Wang, L., & Tian, J. (2021) · Cancer Medicine · doi:10.1002/cam4.4071 · Cited by 10 · see citing works

Pulmonary Toxicities of Immunotherapy

Altan, M., Zhong, L., Shannon, V. R., & Sheshadri, A. (2021) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-79308-1_14 · Cited by 10 · see citing works

Immune checkpoint inhibitor therapy and outcomes from SARS-CoV-2 infection in patients with cancer: a joint analysis of OnCovid and ESMO-CoCARE registries

Cortellini, A., Dettorre, G. M., Dafni, U., Castelo-Branco, L., Lambertini, M., Gennatas, S., Angelis, V., Sita-Lumsden, A. R., Rogado, J., Pedrazzoli, P., et al. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-005732 · Cited by 10 · see citing works

Immune Checkpoint Inhibitor-Induced Myocarditis, Myositis, Myasthenia Gravis and Transaminitis: A Case Series and Review

Siu, D. H. W., O'Neill, R. S., Harris, C. A., Wang, J., Ardolino, L., Downton, T. D., Tong, M., Hong, J. H., Chin, V. T., Clingan, P. R., et al. (2022) · Immunotherapy · doi:10.2217/imt-2021-0225 · Cited by 10 · see citing works

Glucagon-like peptide-1 receptor agonists and Wernicke encephalopathy: A pharmacovigilance study and literature review

Lev, D., Leibowitz, A., Lang, A., Shlomai, G., Twig, G., Eden-Friedman, Y., Engel, T., Cukierman-Yaffe, T., Dankner, R. S., Gerstein, H. C., et al. (2026) · Clinical Nutrition · doi:10.1016/j.clnu.2025.106571 · Cited by 12 · see citing works

Immune Checkpoint Inhibitor-Induced Hepatic Injury: A Clinicopathologic Review

Taherian, M., Chatterjee, D., & Wang, H. (2022) · Journal of Clinical and Translational Pathology · doi:10.14218/jctp.2022.00017 · Cited by 9 · see citing works

The other immuno-PET: Metabolic tracers in evaluation of immune responses to immune checkpoint inhibitor therapy for solid tumors

Levi, J., & Hong, S. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1113924 · Cited by 9 · see citing works

Pemphigus vulgaris as an immune-related adverse event in recurrent metastatic esophageal squamous cell carcinoma treated with ipilimumab plus nivolumab: a case report and literature review

Nakamura, H., Shionoya, A., Arihara, Y., Hayasaka, N., Kubo, T., Usami, M., Sugita, S., Uhara, H., & Takada, K. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1259071 · Cited by 9 · see citing works

Association of Rare Immune-Related Adverse Events to Survival in Advanced Cancer Patients Treated with Immune Checkpoint Inhibitors: A Real-World Single-Center Cohort Study

Kuusisalo, S., Koivunen, J. P., & Iivanainen, S. (2022) · Cancers · doi:10.3390/cancers14092276 · Cited by 9 · see citing works

Abdominal pain accompanied by elevated serum inflammatory markers and biliary enzymes for diagnosing immune checkpoint inhibitor-induced sclerosing cholangitis

Yamamoto, T., Mizuno, K., Ito, T., Yokoyama, S., Yamamoto, K., Imai, N., Ishizu, Y., Honda, T., Ishikawa, T., Kanamori, A., et al. (2023) · Investigational New Drugs · doi:10.1007/s10637-023-01366-3 · Cited by 9 · see citing works

Tumor Lysis Syndrome with CD20 Monoclonal Antibodies for Chronic Lymphocytic Leukemia: Signals from the FDA Adverse Event Reporting System

Xia, S., Ma, J., Raschi, E., Ma, R., Zhang, B., Guo, L., Noguchi, Y., Sarangdhar, M., Gong, H., & Yan, M. (2023) · Clinical Drug Investigation · doi:10.1007/s40261-023-01308-0 · Cited by 9 · see citing works

Drug-induced coagulopathies: a real-world pharmacovigilance study using the FDA adverse event reporting system

Lu, Y., Xu, Q., & Zhu, S. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1486422 · Cited by 8 · see citing works

Psychiatric disorders with antiseizure medications in children: an analysis of the FDA adverse event reporting system database

Gui, J., Wang, L., Meng, L., Zhang, X., Ma, J., & Jiang, L. (2025) · Acta Epileptologica · doi:10.1186/s42494-025-00223-5 · Cited by 8 · see citing works

Defining the correlation between immune-checkpoint inhibitors-related adverse events and clinical outcomes: a narrative review

Abdihamid, O., Athman, A., & Rugambwa, T. K. (2021) · ecancermedicalscience · doi:10.3332/ecancer.2021.1314 · Cited by 9 · see citing works

Gastrointestinal disorders as immune-related adverse events

Balducci, D., Quatraccioni, C., Benedetti, A., Marzioni, M., & Maroni, L. (2021) · Exploration of Targeted Anti-tumor Therapy · doi:10.37349/etat.2021.00039 · Cited by 8 · see citing works

Anti-PD-1 and Regorafenib Induce Severe Multisystem Adverse Events in Microsatellite Stability Metastatic Colorectal Cancer: A Case Report

Yang, Y., Xu, L., Wang, D., Hui, B., Li, X., Zhou, Y., Chen, X., & Gu, Y. (2021) · Immunotherapy · doi:10.2217/imt-2020-0327 · Cited by 8 · see citing works

Immune checkpoint inhibitors-induced diabetes mellitus (review)

Chen, J., Hou, X., Yang, Y., Wang, C., Zhou, J., Miao, J., Gong, F., Ge, F., & Chen, W. (2024) · Endocrine · doi:10.1007/s12020-024-03942-w · Cited by 7 · see citing works

A Real-World Comparison of the Safety Profile for Immune Checkpoint Inhibitors in Oncology Patients

Alwhaibi, A. M., Alenazi, M. A., Alghadeer, S. M., Mansy, W., Alsaif, R., Abualreesh, N. E., Alanazi, R. J., Alroumi, A., & Alanazi, S. A. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14020388 · Cited by 7 · see citing works

Outcomes of immune checkpoint inhibitor‐induced liver toxicity managed by hepatologists in a multidisciplinary toxicity team

Ito, T., Mizuno, K., Yamamoto, T., Yasuda, T., Yokoyama, S., Yamamoto, K., Imai, N., Ishizu, Y., Honda, T., Hama, M., et al. (2024) · Hepatology Research · doi:10.1111/hepr.14043 · Cited by 7 · see citing works

Association Between PD-L1 Inhibitor, Tumor Site and Adverse Events of Potential Immune Etiology Within the US FDA Adverse Event Reporting System

Abdel-Rahman, O. M. (2021) · Immunotherapy · doi:10.2217/imt-2021-0068 · Cited by 7 · see citing works

Type 1 diabetes with immune checkpoint inhibitors: A systematic analysis of clinical trials and a pharmacovigilance study of postmarketing data

Zhu, J., Luo, M., Liang, D., Gao, S., Zheng, Y., He, Z., Zhao, W., Yu, X., Qiu, K., & Wu, J. (2022) · International Immunopharmacology · doi:10.1016/j.intimp.2022.109053 · Cited by 8 · see citing works

Immune-Related Adverse Event Likelihood Score Identifies “Pure” IRAEs Strongly Associated With Outcome in a Phase I-II Trial Population

Mazzarella, L., Giugliano, F., Nicolò, E., Espósito, A., Crimini, E., Tini, G., Uliano, J., Corti, C., D’Amico, P., Aliaga, P. T., et al. (2023) · The Oncologist · doi:10.1093/oncolo/oyad239 · Cited by 7 · see citing works

Immune-related intestinal pseudo-obstruction caused by immune checkpoint inhibitors: case report

Qian, Y., Zheng, Z., Ai, J., Kang, L., Qiu, G., Huang, X., & Zhao, J. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1415117 · Cited by 7 · see citing works

Pulmonary Embolism in a Patient With ADPKD Treated With Tolvaptan: From the Clinical Experience to the Analysis of the Food and Drug Administration Adverse Event Reporting System Registry

Aiello, V., Fusaroli, M., Raschi, E., Palazzini, M., Hu, L., Barbuto, S., Poluzzi, E., & Capelli, I. (2021) · Kidney International Reports · doi:10.1016/j.ekir.2021.06.028 · Cited by 7 · see citing works

The impact of immune-related adverse events on survival outcomes in a racially diverse population, with a focus on non-Hispanic Black patients

Radwan, A., Jani, C., Omari, O. A., Patel, M., Burns, L., Mackay, Z., Li, L., Mahdaviani, K., Davidson, A., Weinberg, J., et al. (2024) · The Oncologist · doi:10.1093/oncolo/oyae279 · Cited by 6 · see citing works

Mechanisms underlying immune-related adverse events during checkpoint immunotherapy

Zhou, X., Chen, X., Han, L., & Liu, H. (2022) · Clinical Science · doi:10.1042/cs20210042 · Cited by 6 · see citing works

Pulmonary Immune-Related Adverse Events of PD-1 Versus PD-L1 Checkpoint Inhibitors: A Retrospective Review of Pharmacovigilance

Ebinama, U., Sheshadri, A., Anand, K., & Iyer, S. P. (2023) · Journal of Immunotherapy and Precision Oncology · doi:10.36401/jipo-22-38 · Cited by 6 · see citing works

Real world comparison of immune-related adverse events with nivolumab-relatlimab versus ipilimumab-nivolumab in patients with advanced cutaneous melanoma

Kielkowski, B. N., Mansour, D., Ebbert, B., Seago, K., Wen, S., Li, H., & Barrett, C. (2024) · Journal of Oncology Pharmacy Practice · doi:10.1177/10781552241303698 · Cited by 6 · see citing works

Evolving Landscape in Liver Transplantation for Hepatocellular Carcinoma: From Stage Migration to Immunotherapy Revolution

Cesario, S., Genovesi, V., Salani, F., Vasile, E., Fornaro, L., Vivaldi, C., & Masi, G. (2023) · Life · doi:10.3390/life13071562 · Cited by 6 · see citing works

Knowledge gap about immune checkpoint inhibitors among rheumatologists and medical students: a survey

da Silva, G. F. M., Landim, J. I. V. D., BRASIL, L. T. D. S., Plens, I. C. M., Silva, A. L. C., Scheinberg, M. A., & Rocha, F. A. C. (2020) · Rheumatology International · doi:10.1007/s00296-020-04674-6 · Cited by 6 · see citing works

Capecitabine-associated gastrointestinal ulceration, haemorrhage, and obstruction: a pharmacovigilance analysis based on the FAERS

Wang, Y., Meng, L., & Liu, X. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1412938 · Cited by 5 · see citing works

Immune-related and Common Adverse Events With Programmed Cell Death 1/Programmed Cell Death Ligand 1 inhibitors combined with other Anticancer Therapy for Solid Tumors: A Systematic Review and Meta-analysis

Inoue, T., & Narukawa, M. (2024) · Clinical Oncology · doi:10.1016/j.clon.2024.10.034 · Cited by 5 · see citing works

Fractures Associated with Immune Checkpoint Inhibitors: A Disproportionality Analysis of the World Health Organization Pharmacovigilance Database

Koseki, T., Hamano, H., Hatano, M., Tobe, T., Ieda, R., Nakai, T., Zamami, Y., & Yamada, S. (2025) · Pharmaceuticals · doi:10.3390/ph18030333 · Cited by 5 · see citing works

An Assessment of Extended Pembrolizumab Dosing in Advanced Non-Small-Cell Lung Cancer in the Covid-19 Pandemic

Moffat, G. T., Hanna, L., Hopman, W. M., Fung, A. S., & Gaudreau, P.-O. (2023) · Immunotherapy · doi:10.2217/imt-2022-0257 · Cited by 5 · see citing works

Immune-Related Adverse Events Associated with Immune Checkpoint Inhibitors: A Scoping Review

Tacchi, C., Convertino, I., & Bocci, G. (2026) · Pharmaceuticals · doi:10.3390/ph19020276 · Cited by 4 · see citing works

Real-world data on clinical profile of immune-related adverse events (irAEs) associated with immune checkpoint inhibitors (ICIs) in oncology.

Sudha, S. P., Alhajeri, S., Abdullatif, A., Abdelfattah, N. M., Hadi, Y., Elgezeiry, Y., Hiba, H., Abalı, H., Yetişyiğit, T., Keskin, Ö., et al. (2026) · Journal of Clinical Oncology · doi:10.1200/jco.2026.44.16_suppl.11151

Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance

Martins, F., Sofiya, L., Sykiotis, G. P., Lamine, F., Maillard, M., Fraga, M., Shabafrouz, K., Ribi, C., Cairoli, A., Guex-Crosier, Y., et al. (2019) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-019-0218-0 · Cited by 2,314 · see citing works

Immune-related adverse events associated with immune checkpoint inhibitors: a call to action for collecting and sharing clinical trial and real-world data

Reynolds, K. L., Arora, S., Elayavilli, R. K., Louv, W. C., Schaller, T. H., Khandelwal, A., Rothenberg, M. L., Khozin, S., Guidon, A. C., Dougan, M. L., et al. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-002896 · Cited by 48 · see citing works

Immune-related adverse events associated with immune-checkpoint inhibitors: A single center experience

Samancı, N. Ş., Oruç, K., Bedir, Ş., Çelik, E., Değerli, E., Derin, S., Demirelli, F. H., & Özgüroğlu, M. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz449.007